Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma

Mahsa Eskian, Mir Hojjat Khorasanizadeh, Pier Luigi Zinzani, Tim M. Illidge, Nima Rezaei

Research output: Contribution to journalReview articlepeer-review


Radioimmunotherapy (RIT) is a novel strategy for treating non-Hodgkin lymphoma (NHL). Several studies have shown the promising results of using RIT in NHL, which have led to FDA approval for two RIT agents in treating low grade NHL. In spite of these favorable results in low-grade NHL, most of the aggressive or relapsed/refractory NHL subjects experience relapses following RIT. Although more aggressive treatments such as myeloablative doses of RIT followed by stem cell transplantation appear to be able to provide a longer survival for some patients these approaches are associated with significant treatment-related adverse events and challenging to deliver in most centers. Therefore, it seems reasonable to develop treatment approaches that enhance the efficiency of RIT, while reducing its toxicity. In this paper, novel methods that improve the efficiency of RIT and reduce its toxicity through various mechanisms are reviewed. Further clinical development of these methods could expand the NHL patient groups eligible for receiving RIT, and even extend the use of RIT to new indications and disease groups in future.

Original languageEnglish
Pages (from-to)79-91
Number of pages13
JournalInternational Reviews of Immunology
Issue number2
Early online date31 Mar 2019
Publication statusPublished - 2019


  • Enhancing efficiency
  • non-Hodgkin lymphoma
  • novel method
  • pretargeting
  • promoting
  • radioimmunotherapy

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma'. Together they form a unique fingerprint.

Cite this